METTL7A-Overexpressing Stem Cell Composition for Bone Regeneration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional stem cell transplantation for bone regeneration, particularly in cases of extensive bone loss with vascular damage, faces challenges such as poor viability and osteogenic differentiation of transplanted cells, leading to inadequate therapeutic outcomes.

Innovation Solution

Development of a composition containing METTL7A gene-overexpressing stem cells, achieved through a minicircle vector, which enhances osteogenic differentiation and viability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional stem cells are transplanted for bone regeneration, then the procedure is simple and cost-effective, but the transplanted cells show poor viability and osteogenic differentiation ability, leading to inadequate therapeutic outcomes

Engineering Contradiction:

Improvetherapeutic outcomeVSAvoidcell preparation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by modifying the genetic expression parameters of stem cells through METTL7A gene overexpression. This changes the biological properties of the cells to enhance their viability and osteogenic differentiation ability, directly addressing the poor therapeutic outcome while maintaining the simplicity of the transplantation procedure

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The METTL7A gene acts as an intermediary element that mediates between the transplanted stem cells and the bone regeneration process. By introducing this genetic mediator, the cells gain enhanced capabilities for survival and differentiation in the target tissue, resolving the contradiction between simple transplantation and effective therapeutic outcome

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If stem cells are transplanted in cases of extensive bone loss with vascular damage, then the treatment addresses severe bone defects, but the transplanted cells are not supplied with blood and are mostly necrotic in the early stages

Engineering Contradiction:

Improvecell viabilityVSAvoidvascular damage impact

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by pre-modifying the stem cells with METTL7A gene overexpression before transplantation. This preliminary genetic modification equips the cells with enhanced anti-necrotic properties and improved survival capabilities, allowing them to resist the harmful effects of vascular damage and poor blood supply in the early stages after transplantation

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The METTL7A gene overexpression is performed as a preliminary action before cell transplantation. This advance preparation enhances the cells' intrinsic viability and ability to withstand ischemic conditions, enabling them to survive and function in the challenging environment of extensively damaged bone tissue with compromised vascular supply

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12551505B2Composition for bone regeneration comprising METTL7A overexpressing stem cells, method for preparing same, and cell therapy product comprising same

Publication Date: 2026.02.17 DONGGUK UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

AI summary

The present invention relates to a composition for bone regeneration comprising METTL7A-overexpressing stem cells, a method for preparing the same, and a cell therapy product comprising the same. According to the invention, it is possible to enhance the osteogenic differentiation ability and viability of stem cells compared to conventional stem cell therapy products for bone regeneration.